CK0802
Identification
- Generic Name
- CK0802
- DrugBank Accession Number
- DB15866
- Background
CK0802 is an off-the-shelf product composed of allogeneic umbilical cord blood derived regulatory T-cells (T-Reg cells), which can be used intravenously and without HLA matching.1 On the surface of these T-Reg cells, T-cell lung homing markers are expressed.
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Allogeneic Umbilical Cord Blood Derived Regulatory T-Cells
- External IDs
- CK0802
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
T-Reg cells engage with antigen-presenting cells lining the alveolar epithelium. This likely results in disarmament and dampening of the cytokine storm — seen with a study where there was a rapid decline in peripheral biomarkers and decreased blood levels of inflammatory cytokines after treatment with CK0802. It is also a possibility that these cells can calm inflammation where it is most active and act discriminately, avoiding general immunosuppression. This therapy is currently being investigated against COVID-19 acute respiratory distress syndrome (ARDS), inflammatory diseases, and autoimmune disorders.1
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- H7DFT9JF6M
- CAS number
- Not Available
References
- General References
- CISION PR Newswire: Johns Hopkins Reports Promising Clinical Data in COVID-19 ARDS Treated with Cellenkos' Cord Blood T-Regulatory Cells [Link]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Treatment Acute Respiratory Distress Syndrome (ARDS) / Coronavirus Disease 2019 (COVID‑19) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at September 21, 2020 14:30 / Updated at September 22, 2020 13:00